Transcriptomic Ovarian Cancer Datasets


[Up] [Top]

Documentation for package ‘MetaGxOvarian’ version 0.99.7

Help Pages

dupplicates a list containing the names of patients that are believed to be dulicates across datasets
E.MTAB.386 Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.
GSE12418 Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors.
GSE12470 Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
GSE13876 Survival-related profile, pathways, and transcription factors in ovarian cancer.
GSE14764 A prognostic gene expression index in ovarian cancer - validation across different independent data sets.
GSE17260 Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
GSE18520 A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.
GSE19829 Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
GSE20565 A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.
GSE2109 IGC EXpression Project for Oncology
GSE26193 miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response.
GSE26712 A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.
GSE30009 Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
GSE30161 Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
GSE32062 High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
GSE32063 High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
GSE44104 COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
GSE49997 Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.
GSE51088 POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
GSE6008 Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
GSE6822 Classification of ovarian tumor samples
GSE8842 Analysis of gene expression in early-stage ovarian cancer.
GSE9891 Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
loadOvarianEsets Function to load ovarian cancer expression sets from the Experiment Hub
PMID15897565 Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
PMID17290060 An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
PMID19318476 Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
TCGA.RNASeqV2 Integrated genomic analyses of ovarian carcinoma.
TCGAOVARIAN Integrated genomic analyses of ovarian carcinoma.